Page 1

1 Hypera pharma Hypera Pharma reports Net Revenue growth of 43.7 % in 1Q21 , with EBITDA from Continuing Operations expansion of 45.6 % São Paulo , April 23 , 2021 - Hypera S.A. ( " Hypera Pharma ” or “ Company ” ; B3 : HYPE3 ; Bloomberg : HYPE3 BZ ; ISIN : BRHYPEACNORO ; Reuters : HYPE3.SA ; ADR : HYPMY ) announces its financial results for the 1st quarter of 2021. Financial data disclosed here are taken from the consolidated financial statements of Hypera S.A. , prepared in accordance with the Brazilian Accounting Pronouncement Committee ( CPC ) and International Financial Reporting Standards ( IFRS ) issued by the International Accounting Standards Board ( IASB ) . 1Q21 Highlights • Net revenue of R $ 1,170.9 million in the quarter , or 43.7 % higher than 1Q20 • EBITDA from Continuing Operations of R $ 362.0 million , or 45.6 % higher than 1Q20 • Net Income of R $ 305.1 million , an increase of 28.1 % over 1Q20 • Sell - out growth of 11.5 % ¹ in 1Q21 , or 2.0 p.p. above the market² , according to IQVIA • • Interest on Equity Approval of R $ 194.8 million in 1Q21 , or 5 % higher than 1Q20 Completion of Takeda brands and Simple Organic acquisitions • Table 1 Acquisition of a minority stake in Consulta Remédios , 2nd investment made by Hypera Ventures ( R $ million ) 1Q20 % NR 1Q21 % NR A % Gross Revenue , net of Returns and Unconditional Discounts 911.6 111.8 % 1,331.5 113.7 % 46.1 % Net Revenue 815.0 100.0 % 1,170.9 100.0 % 43.7 % Gross Profit 543.1 SG & A ( ex - Marketing and R & D ) Research & Development Marketing 66.6 % 752.8 ( 145.2 ) -17.8 % ( 166.9 ) ( 32.0 ) -3.9 % ( 40.4 ) ( 182.6 ) -22.4 % ( 214.7 ) 64.3 % 38.6 % -14.3 % 14.9 % -3.4 % 26.1 % -18.3 % 17.6 % EBITDA from Continuing Operations 248.7 30.5 % 362.0 30.9 % 45.6 % Net Income from Continuing Operations 248.0 30.4 % 307.6 26.3 % 24.1 % Net Income 238.2 29.2 % 305.1 26.1 % 28.1 % EARNINGS CONFERENCE CALL - PORTUGUESE : 04/26/2021 , 11am ( Brasília ) / 10am ( New York ) Webcast : click here / Phone : +55 11 3181-8565 ( code - Hypera ) Replay : +55 ( 11 ) 3193-1012 or +55 ( 11 ) 2820-4012 ( code - 5476238 # ) or website ir.hypera.com EARNINGS CONFERENCE CALL - ENGLISH ( Simultaneous translation ) : 04/26/2021 , 11am ( Brasília ) / 10am ( New York ) Webcast : click here / Phone : US Toll Free +1 412 717-9627 | International +1 412 717-9627 ( code - Hypera ) Replay : +55 ( 11 ) 3193-1012 ( code - 8440138 # ) or website ir.hypera.com Note : 1 Sell - out PPP 1Q21 ( Pharmacy Purchase Price ) , as informed by IQVIA , considers the average purchase price pharmacies and chains . It does not consider the sell - out of the Buscopan family and the brands acquired from Takeda ; 2As informed by IQVIA , it excludes the infant formula segment . IR contacts +55 ( 11 ) 3627-4206 +55 ( 11 ) 3627-4097 ri@hypera.com.br